VUSION
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VUSION (VUSION).
Antifungal; inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell membrane synthesis.
| Metabolism | Not systemically absorbed; minimal hepatic metabolism via CYP enzymes if absorbed. |
| Excretion | Primarily eliminated via biliary/fecal route; minimal renal excretion (<5% unchanged). Approximately 80% of the absorbed dose appears in feces as unchanged drug and metabolites. |
| Half-life | Terminal elimination half-life is approximately 36 hours, reflecting prolonged exposure in stratum corneum and hair follicles; systemic half-life is negligible due to minimal percutaneous absorption. |
| Protein binding | Due to minimal systemic absorption, protein binding data not clinically relevant; in vitro studies suggest >90% bound to plasma proteins (primarily albumin) at systemic concentrations achieved. |
| Volume of Distribution | Not established due to negligible systemic absorption; percutaneous absorption estimated <0.5% of applied dose, so Vd is not clinically meaningful. |
| Bioavailability | Percutaneous absorption is <0.5% of the applied dose; systemic bioavailability is negligible (<1%). |
| Onset of Action | Clinical effect (reduction in erythema, scaling, and pruritus) observed within 2–4 weeks of twice-daily application; onset not defined for systemic effects as absorption is minimal. |
| Duration of Action | Duration of action after discontinuation is not defined; treatment typically continued for 4 weeks. If no improvement, alternative therapy should be considered. Relapse may occur if treatment stopped prematurely. |
Apply a thin layer to the affected area twice daily (morning and evening) for 7 days. Topical use only.
| Dosage form | OINTMENT |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | For infants aged 5 weeks to 12 months, apply a thin layer to the affected area twice daily for 7 days. |
| Geriatric use | No specific dosage adjustment required; use caution due to potential for increased skin sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VUSION (VUSION).
| Breastfeeding | Not known if excreted in human milk. M/P ratio not determined. Due to low systemic absorption after topical application, risk to breastfeeding infant is considered minimal. Use with caution. |
| Teratogenic Risk | No teratogenic effects reported in animal studies; human data insufficient. First trimester: unknown risk; second/third trimester: low systemic absorption likely negligible. Use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to sulconazole or any component of the formulation"]
| Precautions | ["For external use only","Avoid contact with eyes, nose, mouth, or other mucous membranes","Discontinue if irritation or sensitization occurs","Not for ophthalmic or vaginal use"] |
Loading safety data…
| No specific fetal monitoring required. Monitor for local skin reactions at application site. Assess for signs of maternal irritation or hypersensitivity. |
| Fertility Effects | No adverse effects on fertility reported in animal studies. Human data insufficient. Unlikely to impact fertility due to minimal systemic absorption. |